Get the Stockscreener App
1,235.56
2.96%
35.50
After Hours:
1236.01
0.45
+0.04%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,235.56, with a volume of 2.89M.
It is up +2.96% in the last 24 hours and up +9.20% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,200.06
Open:
$1232.88
24h Volume:
2.89M
Relative Volume:
0.89
Market Cap:
$1.10T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
44.48
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+3.01%
1M Performance:
+9.20%
6M Performance:
+11.50%
1Y Performance:
+59.87%
1-Day Range:
$1,222.77
$1,249.45
1-Week Range:
$1,173.93
$1,249.45
52-Week Range:
$623.78
$1,249.45
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,235.56 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
267.24 | 624.26B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
254.65 | 450.11B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
128.86 | 313.12B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
157.03 | 296.69B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Why Eli Lilly Stock Climbed to a Record High Today - AOL.com
Fla. Hospital Says Lilly's 340B Data Requirement Is Onerous - Law360
Migraine Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | GlaxoSmithKline, Merck, Pfizer, Bausch Health, Amgen, Abbvie, AstraZeneca, Eli Lilly - Barchart.com
Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom - The Motley Fool
Why Eli Lilly (LLY) Stock Is Trading Up Today - Yahoo Finance
Form 144 ELI LILLY AND COMPANY For: 7 July By Investing.com - Investing.com Canada
Lilly Endowment (LLY) reports multiple stock sales, May–June 2026 - Stock Titan
Tampa General sues Eli Lilly over alleged 'illegal' cutoff of discounted drug pricing - The Business Journals
Is Eli Lilly (NYSE:LLY) Still A Blue-Chip Leader? - Kalkine Media
Mounjaro from Eli Lilly and Co.weekly injection reshapes US weight-loss market - AD HOC NEWS
Eli Lilly Seen Raising Guidance on Continued GLP-1 Growth -- Market Talk - Moomoo
Eli Lilly Stock Hits a New All-Time High: Has It Gotten Too Expensive to Buy? - The Motley Fool
Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up - Yahoo! Finance Canada
Eli Lilly and Co Stock (LLY) Moved Up by 3.08% on Jul 7: Facts Behind the Movement - TradingKey
Eli Lilly Gains as Investors Lean Into Obesity Franchise Momentum - Quiver Quantitative
Eli Lilly (LLY) Expands Mounjaro Use for Pediatric Diabetes Mana - GuruFocus
Eli Lilly (NYSE:LLY) Faces A Big GLP Test - Kalkine Media
LLY: JPMorgan Raises Eli Lilly Price Target Amid Strong Earnings Outlook - GuruFocus
Eli Lilly stock hits all-time high at 1238.06 USD By Investing.com - Investing.com Canada
LLY Maintained by JP Morgan -- Price Target Raised to $1400 - GuruFocus
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,350 to $1,400 - 富途牛牛
Can anyone catch up to Eli Lilly? - Pharma Voice
Is It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years. - Yahoo Finance
JPMorgan Adjusts Price Target on Eli Lilly to $1,400 From $1,300 - Moomoo
Eli Lilly stock holds the spotlight. Company identity is confirmed. - AD HOC NEWS
Eli Lilly (LLY) Could Be 19% Undervalued Following Medicare GLP 1 Expansion - simplywall.st
Eli Lilly (LLY) Expands R And D Reach With Abbisko And China Drug Handover - Yahoo Finance
Eli Lilly (NYSE:LLY): Can GLP-1 Access Widen? - Kalkine Media
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - The Motley Fool
Eli Lilly and Company (LLY) Fell on Regulatory And Pricing Policy Challenges - Yahoo Finance
Cantor Fitzgerald raises Eli Lilly stock price target on strong outlook - Investing.com
Could Buying Eli Lilly Stock Today Set You Up for Life? (Hint: Yes.) - Yahoo Finance
LLYLilly(Eli) & Co Latest SEC Filings - Finviz
Eli Lilly Stock (LLY) Opinions on Medicare Coverage and Drug Pipeline Advancements - Quiver Quantitative
Should Expanded Medicare GLP‑1 Access and New Oncology Wins Require Action From Eli Lilly (LLY) Investors? - simplywall.st
Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly? - Yahoo Finance
LLY News | ELI LILLY & CO (NYSE:LLY) - ChartMill
Eli Lilly & Co. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Eli Lilly acquisition payday fuels $1M seed round for St. Petersburg biotech startup - The Business Journals
Eli Lilly and Co Stock (LLY) Moved Up by 3.06% on Jul 2: What Signal Does It Send? - TradingKey
Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock? - Yahoo Finance
Top Eli Lilly and Company (LLY) Competitors 2026 - MarketBeat
Charles River Laboratories International (CRL) On Lilly TuneLab Deal And The Valuation Debate - simplywall.st
Eli Lilly (LLY) Faces China Trial Probe While Handing Verzenios Rights To Innovent - simplywall.st
Is Eli Lilly (LLY) One of Billionaire Cliff Asness’ Best Healthcare Stock Picks ? - Insider Monkey
Why Is Eli Lilly (NYSE:LLY) Obesity Pill In Focus? - Kalkine Media
Medicare Expands Access to GLP-1 Drugs, Boosting Eli Lilly (LLY) and Novo Nordisk (NVO) - GuruFocus
Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China - Benzinga
$100 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today - Benzinga
Eli Lilly & Co. highlights its role in innovative diabetes care - AD HOC NEWS
Mounjaro from Eli Lilly & Co.dual-action diabetes drug expands US reach - AD HOC NEWS
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.05%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):